Dr. Thomas J. Lynch Jr. named new president and director of Fred Hutch
Dr. Thomas J. Lynch Jr. will become Fred Hutchinson Cancer Research Center’s new president and director, the organization announced today. Lynch, a well-known cancer leader with expertise in solid tumor research, precision medicine and immuno-oncology, starts at Fred Hutch in February 2020.
Lynch has been a nationally recognized leader in academic medicine for more than three decades. He has served as chairman and CEO of Massachusetts General Physicians Organization, director of Yale Cancer Center, physician-in-chief of Yale’s Smilow Cancer Hospital, professor of medicine at Yale School of Medicine, chief of Hematology-Oncology at Massachusetts General Hospital and professor of medicine at Harvard Medical School.
He was most recently chief scientific officer at Bristol-Myers Squibb, where he led the company’s research and development efforts in cancer, cardiovascular disease, fibrosis and immunoscience. Lynch focused on translational immuno-oncology research that resulted in new therapies and treatments for patients with both solid tumors and hematologic malignancies.
While at Massachusetts General Hospital, he was part of the research team that discovered how targeted therapies could dramatically change outcomes for lung cancer patients with mutations in the EGFR, or epidermal growth factor receptor, gene. This discovery helped to ignite deeper understanding of how molecular profiling can be a key tool in the development of new medicines to treat patients with lung cancer. Lynch has been at the forefront of precision medicine — identifying the best treatments for patients based on the genetic makeup of their specific tumors.
Lynch’s career at Bristol-Myers Squibb, Yale and Mass General has been focused on building collaborative interdisciplinary teams. His work has received team science awards from both the American Association for Cancer Research and the International Association for the Study of Lung Cancer.